Compare Moderna, Inc. (MRNA) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while iShares 1 3 Year Treasury Bond ETF trades at $81.2 (market cap $26.68B). The key difference: Moderna, Inc. is far larger — about 2.9× iShares 1 3 Year Treasury Bond ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| MRNA | SHY | |
|---|---|---|
Market Cap | $78.65B | $26.68B |
Volume | 37,373,437 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $225.00 | $83.18 |
52-Week Low | $22.36 | $81.05 |
Typical Hold Time | 59 Days | 63 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
SHY, a US stock, trades at $81.20 with minimal daily movement (+0.05%). The technical outlook is bearish, with moving averages signaling downward pressure and key indicators like the ADX_12 at 50.39 suggesting a strong trend. Recent corporate actions include scheduled dividends through late 2026, though financial ratios (P/E, P/S, etc.) are unavailable in the current snapshot. Market sentiment is influenced by broader bond market volatility, with news highlighting rising Treasury yields and geopolitical tensions impacting inflation expectations.
The outlook for SHY is cautious amid a bearish technical setup and macroeconomic headwinds, including higher interest rates and inflation concerns. Opportunities may arise from its dividend payments, but risks include sustained bond market sell-offs and economic uncertainty. Investors should weigh the stock's stability against potential volatility from external factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
